https://integrotheranostics.com/summary-block-carosel daily 0.75 2026-01-23 https://integrotheranostics.com/summary-block-carosel/blog-post-title-four-9e9p6-bas48 monthly 0.5 2026-01-23 https://integrotheranostics.com/summary-block-carosel/image1 monthly 0.5 2026-01-23 https://integrotheranostics.com/summary-block-carosel/blog-post-title-two-tmels monthly 0.5 2026-01-23 https://integrotheranostics.com/summary-block-carosel/blog-post-title-three-amjf8 monthly 0.5 2026-01-23 https://integrotheranostics.com/summary-block-carosel/blog-post-title-four-9e9p6 monthly 0.5 2026-01-23 https://integrotheranostics.com/contact daily 0.75 2025-09-26 https://integrotheranostics.com/leadership daily 0.75 2026-01-14 https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/1767630730838-QEHR2MONKOCUEDZDALRT/Scott+Glover.jpg Our Leadership - Scott Glover, Chief Executive Officer Scott is responsible for providing strategic, financial and operational leadership for the organization. Scott is blessed to have over 30 years of leadership and expertise in the diagnostics, medical, life science and pharmaceutical markets. This includes executive-level responsibilities held across Fortune 500, private and start-up organizations. Scott started his career at Abbott Laboratories (diagnostic and device business units), operating in the commercial sector where he held senior positions in the sales and marketing areas. He then moved on to Cardinal Health where he served as Senior VP of Sales and Marketing for the pharmaceutical segment. Scott gained life science experience while serving as Chief Commercial Officer at Sigma-Aldrich. His career also has a private sector and start-up community footprint where he has served as president Dynalabs, a pharmaceutical testing company as well as president of several start-up companies in the Cortex community in St. Louis. He has also gained private investment experience as President of the Health and Medical group with Kingdom Capital. Scott has served on a variety of boards over his career. He currently is serving as a board member for Biblical Business Training (BBT), Undivided Wealth Management and a strategic advisor for the Foundation School. Scott graduated with a Bachelor of Science from Purdue University in Management/Engineering. https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/1767630988068-CWEW9ZSBWV0ABAG40ZOY/Dan+Thompson.jpg Our Leadership - Dan Thompson, Chief Operating Officer Dan is leading the development initiative and commercialization planning for Integro Theranostics, LLC, a Kingdom Capital portfolio company focused on medical device and diagnostic development initially in the area of cancer. Dan has enjoyed a blessed professional career spanning more than 30 years and includes executive leadership as President & CEO as well as Chief Operating Officer in the pharmaceutical arena at GeneriCo as well as a Partner in venture development. Dan’s executive leadership in public organizations has included roles as Chief Compliance Officer, as well as Head of Business Development and Quality Affairs at a women’s healthcare company, Lumara Health and Head of Medical Affairs at KV Pharmaceutical. He has successfully led the development of and drive to product launches and commercial success. He has been a professional mentor to entrepreneurs in the life sciences and medical device-diagnostic sector and an Adjunct Professor to students in the PharmD. curriculum. Dan has contributed to the University of Missouri’s BioDesign Board, has several publications in peer-reviewed journals relating to drug delivery systems and technologies, is a contributing author on four patent submissions and is the author of Little Ways to Little Sanctity. Dan’s educational background includes a Juris Doctorate from St. Louis University School of Law with a Certification in Health Law, a Masters in Molecular Biology from the University of Missouri and a Bachelor of Science from the University of Notre Dame. https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/1696970309033-Q56ZNTA6NJEPEDKKSON1/bobh.jpg Our Leadership - Robert Honigberg, Chief Medical Officer Robert Honigberg, MD, MBA, is a former surgeon and an experienced clinical business leader in a variety of therapeutic areas. Bob taught strategy as an Adjunct Professor of Health Enterprise Management at Kellogg Business School/Northwestern University and is the former Chief Medical Officer of GE Healthcare, Liposcience Inc., and Ethicon Endo-Surgery at Johnson & Johnson. During his 7-year tenure on the Management Board at Ethicon Endo-Surgery, one of the company's focus areas was in the field of surgical oncology and breast cancer. He has also held positions of medical leadership in clinical development, business development, medical affairs strategy, and field medical affairs at Schering-Plough Oncology, Ortho Biotech, CardioDx, Flexion Therapeutics, Baxalta and Shire. He has been on the Advisory Committee of the Aspen Health Stewardship Project and a former interim Chief Medical Officer of the Utilization Review Accreditation Commission (URAC), both located in Washington, DC. Dr. Honigberg graduated from Duke University with a BA in Economics, obtained his medical degree from Northwestern University’s Feinberg School of Medicine, and later an MBA from Northwestern University’s Kellogg School of Management. He undertook his surgical internship and residency at Albert Einstein College of Medicine/Montefiore Medical Center in New York City. Bob is also a consultant with SSI Strategy https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/1765822234128-4KCZTPWASSBBQQZQD9Q9/SamAchilefu-thumb.jpg Our Leadership - Sam Achilefu PhD, Chief Scientific Officer Dr. Achilefu is an expert in the molecular imaging of human diseases, utilizing a multimodal imaging platform to address imaging challenges. He is working on innovative solutions and creating pipeline opportunities to address current needs in cancer intervention. He pioneered the development and use of innovative fluorescent products for cancer imaging. His seminal work in this field of study has resulted in the clinical translation of a product that can detect cancer, irrespective of the tumor type. Dr. Achilefu is a champion for leveling the playing field in health care delivery by promoting objective medical decisions in the clinic. A notable example the first wearable cancer imaging goggle system he developed to illuminate cancer cells, which guide surgeons in the operating room to ensure that no cancer cells are left behind after surgery. He has managed large collaborative federally funded research programs and centers and worked in a multidisciplinary platform to enhance research productivity and impact. Dr. Achilefu provides opportunities to a diverse pool of trainees in medicine, science, and engineering. He is a member of the Scientific Advisory Board of the National Cancer Institute’s intramural Molecular Imaging Program. In 2020, the U.S. Secretary of Health and Human Services appointed him to serve as a member of the National Advisory Council for Biomedical Imaging and Bioengineering (NACBIB). Dr. Achilefu is internationally recognized for his contributions to science, engineering, and medicine, as evidenced by his induction to the National Academy of Medicine, National Academy of Inventors, the Royal Society of Medicine, International Society for Optics and Photonics Engineers (SPIE), American Association for the Advancement of Science, the American Institute for Medical and Biological Engineering, Royal Society of Chemistry, and Optical Society of America. He has published over 300 scientific papers and is an inventor on 65 issued U.S. patents. In addition, Dr. Achilefu has received over 30 local, national, and international honors and awards for research excellence. These include the Carl and Gerty Cori Faculty Achievement Award (Washington University in St. Louis), Distinguished Investigator Award (Department of Defense Breast CancerResearch Program and the Academy for Radiology & Biomedical Imaging Research), and the Britton Chance Biomedical Optics Award (SPIE). https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/1765822370915-LI9UC7GNBSNX04NIE338/TitoGonza%CC%81lez-thumb.jpg Our Leadership - Jesús (Tito) González Ph.D., Chief Technology Officer Dr. Gonzalez (Tito) is an R&D and Bio/Medtech leader with a strong record of creatively applying chemistry, biology and device/instrumentation to develop leading technologies, products, services and pharmaceuticals. At Integro, he is responsible for imaging and camera systems/devices for intraoperative clinical cancer visualization and product development. Tito has over 25 years of scientific and leadership experience in both public and private companies. He is author/inventor on over 75 scientific publications and issued U.S. patents. Tito graduated cum laude from Rice University, Chemistry BA, and received his Ph.D. in Chemistry from Princeton University. He was a postdoctoral fellow at the Howard Hughes Medical Institute working with Professor Roger Y. Tsien at UCSD where they co-invented voltage-sensitive FRET cellular probes. Tito has played an integral role in the discovery, development, and commercialization of many fluorescence-based technologies utilizing chemical probes and device/instrumentation that have been used for research, diagnostic, drug discovery, and therapeutic applications. As Chief Scientific Officer at Avelas Biosciences, he led the discovery and development of the real-time intraoperative cancer visualization drug AVB-620 (pegloprastide) through IND, Phase Ib PoC, and Phase II/III pivotal clinical evaluation in breast cancer patients. Tito was a recipient of the 2025 Lasker~DeBakey Clinical Medical Research Award for playing a key role in developing a novel treatment for cystic fibrosis. https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/1767630885103-BYOQMDKXK0F0HFH7D8VY/Nick+Staten.jpg Our Leadership - Nick Staten, VP of Product Development Nick is leading product development for Integro Theranostics with a primary focus on the CancerVision™ Goggles. He has worked for over 32 years for Fortune 500 companies and start-up companies in the pharma/biotech, medical device, and agriculture industries as well as 3 years at Washington University School of Medicine. His projects and products include small molecule drugs, biotherapeutics/biologics, and medical devices (including diagnostics) to treat a variety of diseases. He has broad technical, operational, and leadership experience in research, development, and manufacturing. He also has Quality Systems and Regulatory experience and has helped submit six medical device and drug applications to the FDA since 2012. Nick has over 30 peer-reviewed publications and several issued patents. He has led genomics-based groups responsible for cloning, high-throughput DNA sequencing, protein engineering and expression, and gene expression profiling, and he has been responsible for coordinating several technology development projects with several major life science companies. Nick also established and/or managed numerous collaborations in the area of translational research and clinical studies with leading institutions including Johns Hopkins University, Harvard University/Beth Israel Hospital, Columbia University, Washington University, Mayo Clinic, Cleveland Clinic, and The Hebrew University of Jerusalem. Nick has a Bachelor of Science degree in Microbiology from the University of Illinois (Champaign-Urbana). https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/1765822717434-ZK2SMWDMFDG2YZFDYZKE/BrianCudney-thumb.jpg Our Leadership - Brian Cudney, Director of Pharmaceutical Development Brian Cudney has more than 20 years of experience in the pharmaceutical industry, focusing on research and development (R&D), analytical development, technical transfer and scale-up of pharmaceutical products in a variety of dosage forms. Cudney also has extensive experience with regulatory strategies (US and OUS), maintaining regulatory compliance, intellectual property protection, technical writing, contract manufacturing and formulation development for a variety of different dosage forms and drug substances. https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/1650994288454-WPTBK21MVU7JJ8CZV42R/2021-03-Marie-Kuker-Headshot-e1632140762437-700x700.jpg Our Leadership - Marie Kuker, Director of Regulatory Affairs Marie is the founder and president of Kuker Regulatory Consulting, a consulting firm specializing in biopharmaceutical regulatory affairs and compliance. She has more than 35 years of experience in the pharmaceutical industry, most recently as head of global regulatory affairs for 3M Pharmaceuticals and Drug Delivery Systems before founding her consultancy in 2007. She is Regulatory Affairs Certified and an appointed Fellow of the Regulatory Affairs Professionals Society. She is an Executive in Residence at the Technology Commercialization Discovery Launchpad at the University of Minnesota and Adjunct Assistant Professor in the Center for Orphan Drug Research, Department of Experimental and Clinical Pharmacology. She also teaches drug/device regulatory affairs in a Masters of Science program at St. Cloud State University. Marie received her Bachelor of Science in Pharmacy from the University of Minnesota. https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/1765822755774-AYHSUAQ7FTCOHRR6MYQ0/JimJoffrion-thumb.jpg Our Leadership - Jim Joffrion, Director of Clinical Operations Jim Joffrion is supporting the clinical and regulatory efforts of Integro Theranostics. He has over 35 years’ experience in the biotechnology and pharmaceutical industry developing robust clinical trial and regulatory strategies and the creation and management of highly effective global clinical trial programs. He has directed or participated in the successful completion of over 400 Phase I, II, III and IV clinical trials in multiple indications including oncology, respiratory infections, asthma/allergy, cardiovascular, women’s health, dermatology, ultra-rare indications, autoimmune disorders, hematology, critical care and gastro-enterology. He has been responsible for the strategic management of multi-million-dollar projects as well as domestic and international regulatory strategy resulting in the successful filing of over 20 INDs, 5 CTAs, numerous ANDAs and 2 NDAs which were ultimately approved. Jim has experience executing clinical trials in North, Central and South America, Eastern and Western Europe and the Asia/Pacific region. Jim has developed solid working relationships with world experts, key opinion leaders, and respected principal investigators throughout the world and leverages these relationships to ensure the proper design, staffing, implementation, and execution of various clincial programs in multiple indications. He has led teams of over 100 clinical research professionals. He is an expert in GCP guidelines as well as FDA and ICH rules and regulations. He has co-authored 18 research papers and presentations. Jim received a Bachelor of Science in biology at Lamar University, Beaumont, Texas and has been a certified PMP since 1999. https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/1765822834536-YG2A6OZ6S6DYOXKCOCHJ/TomMcMonagle_thumb2.jpg Our Leadership - Tom McMonagle, Clinical Development Manager Tom supports the clinical development and project mgmt roles within the company. He brings experience from both large pharmaceutical companies and early-stage biotechs. Tom has a strong foundation in clinical development, regulatory strategy, and program execution, with a focus on building scalable systems, accelerating development timelines, and aligning cross-functional teams around key milestones. His experience spans end-to-end clinical trial execution in rare disease and digital health, global regulatory submissions, and system implementation initiatives in collaboration with technology vendors. He has also led regulatory and operational transformation projects for global life sciences clients, including organizational redesign, process optimization, and digital enablement Tom holds a strong track record of accelerating program timelines, building regulatory infrastructure, and bridging communication between clinical, regulatory, and executive stakeholders to drive product development forward. https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/1765822796929-MEY4DTPN3LPBWIP8KW1V/NicolePeterson-thumb.jpg Our Leadership - Nicole Peterson, Project Lead As the Administrative Liaison, Nicole focuses on the daily operations of business administration and office management. She is blessed to have over 29 years of experience in Educational Leadership and Administration. Her other positions included serving as a Program Director for the YMCA of Greater St. Louis, Accreditation Specialist for Missouri Accreditation for Early Education, Registrar for the Ferguson Florissant School District, and owner of Visions Training and Consulting Services. https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/1767631171407-VYRCT92TOXB8U30TX1L4/BRIAN+EDITED.jpg Our Leadership - Brian Bennet, Leadership Institute Director As Director of Kingdom Capital’s Leadership Institute, Brian focuses on partnering with commercial and philanthropic leaders to cultivate values enhanced organizations. The Institute is focused on both the role of management in shaping culture and the role of culture in contributing to organizational health and performance. Brian is blessed with nearly 16 years of organizational development and leadership experience. This includes executive-level responsibilities within human resource management and organizational strategy. He is a certified coach by the International Coaching Federation and has coached leaders across the private, social, and public sectors. Brian is passionate about helping leaders harness the strengths of their unique leadership profile while adapting to the needs of their team, organization, and environment. He is also certified as a Behavioral Analyst by Target Training International and by Korn Ferry in their Leadership Architect competency model. He has masters degrees in both business administration and organizational leadership. https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/1767631103770-1B2CIXH6Q5SDBHV5V1H1/DAN+EDITED.jpg Our Leadership - Daniel Mintner, Chief Financial Officer and Investment Director Daniel serves as the Chief Financial Officer & Investment Director for Kingdom Capital, where he works with the firm’s portfolio companies focusing on value creation through go-to-market strategies and product-market fit and partners with key stakeholders through all stages of the investment cycle. Prior to joining Kingdom Capital, Daniel served as the Chief Development Officer for a private equity backed multi-unit consumer services business, where he led the company’s M&A and divestiture strategies. Daniel has served in previous roles with private equity and venture capital firms in the capacity of Senior Associate and Financial Analyst. Prior to his tenure in the private market sector, he worked in the financial services industry for Scottrade, a St. Louis, MO based online brokerage company, serving as a general securities principal and branch office manager. Daniel received his MBA in Oil & Gas Management from RGU Aberdeen Business School in Aberdeen, Scotland, and his BS in Personal Financial Planning from the University of Missouri. https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/1768406976680-JOTWAGUZUWW7UI6IT2IP/Sean+Sickles.jpeg Our Leadership - Sean Sickles, Financial Analyst https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/1680540807458-1VUSVM9OTR761C5EFK0A/Dave+Steward+Picture+2023.jpg Our Leadership - Dave L. Steward, Chairman of the Board David L. Steward, Founder and Chairman of World Wide Technology was born in Chicago, Illinois, and moved with his family shortly thereafter to the small rural town of Clinton, Missouri. After graduating from Central Missouri State University in 1973, Mr. Steward relocated to St. Louis, Missouri. He was the first person of color ever hired by Missouri Pacific Railroad Company to sell rail services. Upon leaving Missouri Pacific Railroad Company, he joined Federal Express as a senior account executive. During his tenure at FedEx, Mr. Steward was recognized as salesman of the year and was inducted into the company’s sales hall of fame in 1981. After founding two successful startup companies, Mr. Steward founded World Wide Technology in 1990. Steward and his executive team have built what started as a small logistics/ transportation audit company into a leading systems integrator and supply chain solutions provider with over 5,000 employees globally and $13 billion in revenue. Mr. Steward has been married to his wife, Thelma, for 43 years. Their son, David L. Steward II, CEO of Polarity Ltd, is married to Mary and they have two sons, Trey and Julian. Their daughter, Kimberly Steward, is CEO of K Period Media. Mr. Steward is a member of the Horatio Alger Association of Distinguished Americans and serves on their Board of directors. He also serves on the boards National Academy Foundation (NAF), United Way of Greater St. Louis, Washington University, Variety the Children’s Charity of St. Louis, Boy Scouts of America Great St. Louis Area Council and many other organizations. Under Mr. Steward’s leadership, WWT has grown to be the most successful business in the history of the Government’s 8A disadvantaged business and small business program. The company has successfully partnered with the DOD, various security agencies, NIH and many other civilian agencies. The company has also been issued clearances at the highest level. In addition to graduating from Central Missouri State University, Mr. Steward holds an Honorary Doctor of Laws from Washington University, as well as Honorary Doctorates in Humane Letters from numerous colleges and universities. Mr. Steward was the first non-engineer to be awarded the Black Engineer of the Year Award. In 2018, Mr. Steward was presented with Boy Scouts of America’s national-level Silver Buffalo Award for distinguished service. Mr. Steward and his wife are involved in many philanthropic and community efforts. “I don’t have a business philosophy and a personal philosophy. They are one and the same that I live by 24/7. My wife, Thelma and I come from humble backgrounds, and we have been blessed with more prosperity than we could have imagined when we were young. It is a blessing for us to give to others.” https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/1767631268993-GA7TTOU62VFHAR0EL9F1/B+EDITED.jpg Our Leadership - Brandon K. Mann, Vice Chairman of the Board Brandon has been blessed with more than 25 years of diverse executive and board leadership experience. He is the Co-Founder, Managing Partner and CEO of Kingdom Capital, a values-driven private investment and philanthropic firm that seeks to transform the world through a virtuous cycle of capital. Brandon serves as an advisor to the Board of Directors of World Wide Technology, a global technology solutions firm. Brandon is the Founder and Executive Chairman of Biblical Business Training, a global non-profit ministry that helps people apply Biblical principles at work. He is the co-author of Leadership By The Good Book: Timeless Principles for Making an Eternal Difference, to be published May 2020. Prior to founding Biblical Business Training, Brandon served in a variety of key executive and board roles helping develop the country’s largest privately held commercial real estate services firm. Brandon also has served on a wide variety of non-profit and ministry leadership and board roles, including University of Missouri, United Way, Bonhomme Church, Kirk Day School, and Westminster Christian Academy. Brandon graduated top of his BSBA and MBA programs at the University of Missouri in 1994 and 1996 respectively. Originally from Hannibal, Missouri, Brandon is married to his high school sweetheart, Lisa, and they are blessed with three children: Logan, Kaitlyn, and Gavin. https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/1768407987082-P60OFF8PEPRZIJOFCBGJ/DeanVandeKamp.jpg Our Leadership - H. Dean VandeKamp, Strategic Advisor Dean is a former EY Partner where he led national practices (including cybersecurity) and served as a coordinating partner for public and large private companies. At EY he worked in the audit, consulting, and transaction areas for global companies in several industries including industrial manufacturing, healthcare, insurance, and agriculture. After EY Dean served as a GP with Cultivation Capital, a venture capital firm in the life sciences and technology space, and also with private equity (franchise retail) companies and boards. His experience with startup companies has given him insights into fostering innovation and understanding disruptive risks associated with advanced and emerging technologies. Dean received his MBA at the University of Colorado – Denver and his undergraduate double major in Accounting / Information Systems at Dordt College and has the following certifications: Certified Public Accountant, Certified Fraud Examiner, Certified Information Systems Auditor, and a National Association of Corporate Directors (NACD) Fellow. He has remained active with charitable organization work and industry association affiliations throughout his career and currently serves as a Trustee of Biola University and on the Boys Hope Girls Hope of St. Louis Board, a nonprofit nurturing and guiding academically capable and motivated children in need to become well educated, career-ready men and women. https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/1744600000850-DVN9R2AHGNO6VXLPGQN4/Screenshot+2025-04-13+at+10.05.49%E2%80%AFPM.png Our Leadership - Cory Berkland PhD, Strategic Advisor https://integrotheranostics.com/about daily 0.75 2026-01-23 https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/1648749973869-KIKFYPVRSRPBPO6YKQWO/IT-circle-arrow-lightblue.jpg About https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/1648750182311-FB3ATYUF8QOHUS9DX0VS/IT-logo-overimagejpg.jpg About https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/1402a931-dca9-4526-8be6-ffe208a6b420/Entry-Sign+%281%29-11.jpg About - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/3e136eb4-36ea-4683-a516-75ce2eef9e5a/Dave-Steward.jpg About - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/13c40756-8420-4330-bffb-c68c327e5600/Washington-University-in-St.-Louis-School-of-Medicine-Interview-Prep-SQ.jpg About - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/62c6b691-1d10-4ef3-a614-35d69473e660/Shield+Values+Blue.png About Integro Theranostics embodies the SHIELD values, which are the heart of Kingdom Capital’s investment strategy. The SHIELD values are Biblically-based and rooted in the faith of Kingdom Capital’s founders, David L. Steward and Brandon K. Mann. https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/445d0946-69d8-40fc-a34d-854e57f8849e/IT-Ecosystem-FINAL.png https://integrotheranostics.com/samuel-achilefu daily 0.75 2025-11-11 https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/71cc0de7-6059-49f3-887b-693c8635c88d/achilefu-desktop.jpg Our Inventor: Sam Achilefu, PhD - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/f996d11d-1cdc-4251-8349-4d6b58a89cdb/Star+3.31.22.png Our Inventor: Sam Achilefu, PhD - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://integrotheranostics.com/cancers daily 0.75 2026-01-27 https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/f996d11d-1cdc-4251-8349-4d6b58a89cdb/Star+3.31.22.png Cancers - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/63235c18-d959-45d5-8bba-78104a548779/IT-infographic-1in5-v2_FINAL.png https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/c67a02df-162c-448d-ab54-fcb9fe5da5c7/Asset+3.png https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/b856a30d-15cc-487c-914b-5e463daf9f47/IT-infographic-5Years-v2_FINAL.png https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/7aac7f88-6e09-4ab8-b940-5983f4dd7159/IT-infographic-EarlyDiagnosis-v2_FINAL.png https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/129810d1-d825-4a3d-9f11-bbb495775482/IT-infographic-NoTreatment-v2_FINAL.png https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/976bb9a3-97ff-4a1c-9e9a-af4e66d1740c/IT-infographic-SurgicalTreatment-v2_FINAL.png https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/4894a7b5-a95c-4306-b931-b05af94484d4/Press+Release_v2a.png https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/3143dd31-2265-4f13-bf19-a5ff5b702a7f/PSIMI-Poster_11-11-2025_FINAL.png https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/f3cbec39-3c48-445f-bec6-d214f0e01dbb/Press+Release_v2b.png https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/314d2a8b-f6aa-48a8-a02c-88dd9d52c47f/IT-pipeline-v4_FINAL-transparent.png Cancers - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/f996d11d-1cdc-4251-8349-4d6b58a89cdb/Star+3.31.22.png Cancers - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://integrotheranostics.com/home daily 1.0 2026-01-23 https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/687b2479-a4bf-4a87-a6fa-0146699e878f/IntegroTheranosticsLogo-reverse_burst.webp https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/025296e8-6f33-44ee-a20f-936035162d72/Star+3.31.22.png Home - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/9e4b9387-6aea-4ec0-afe0-f5bf6b6c62f7/slide6+copy.png Home - We use fluorescence to improve patient outcomes. Complete removal of cancerous tumor tissue and lymph nodes is the hallmark of a successful surgery. However, surgeons have limited insight into the success of surgery while in the operating room, resulting in increased risk of cancer recurrence and an elevated rate of repeat surgeries. With Integro’s fluorescent imaging agent, Cronexitide Lanocianine (CXL, formerly LS301), surgeons can see the amount and location of cancer cells and differentiate between healthy and cancerous tissue during surgery. https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/6d4668d4-8513-4ab1-b669-04a62de4ebf6/Sam-Integro-Theranostics.jpg Home - Meet Dr. Samuel Achilefu, Scientific Visionary The inventor of Integro’s cutting-edge technologies is a pioneering expert in the Intraoperative Molecular Imaging (IMI) space. https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/e16459d1-edc1-4961-92db-0f55f593400a/Screenshot+2025-04-13+at+9.27.08%E2%80%AFPM.png https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/7fdd0084-6b88-41d9-9883-6b3547986b80/Health-Disparities-Image-Integro.jpg Home - Committed to Addressing Health Disparities Our product development priorities are informed by our commitment to improving disparities in cancer treatment and patient outcomes. Inadequate health insurance, poor access to high-quality detection and treatment, and lack of diversity in clinical trials are just some of the myriad of factors that contribute to cancer health disparities. Integro is committed to developing products that are accessible to all patients and in establishing partnerships to pursue cancer health equity. https://integrotheranostics.com/science-1 daily 0.75 2026-01-27 https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/f996d11d-1cdc-4251-8349-4d6b58a89cdb/Star+3.31.22.png About CXL - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/58b53e23-a415-44fe-a85b-d84cc9eea53a/Enhanced+Detection.png About CXL - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/852cfbad-86b9-484c-b87d-8a33a98b6a03/Broad+Indications.png About CXL - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/5c988c82-945b-4202-913a-79bfab408256/Data+Insights.png About CXL - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/54d1c186-3836-4a75-8f24-d48e3d092729/Screenshot+2025-04-13+at+9.27.08%E2%80%AFPM.png https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/314d2a8b-f6aa-48a8-a02c-88dd9d52c47f/IT-pipeline-v4_FINAL-transparent.png https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/f996d11d-1cdc-4251-8349-4d6b58a89cdb/Star+3.31.22.png https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/3143dd31-2265-4f13-bf19-a5ff5b702a7f/PSIMI-Poster_11-11-2025_FINAL.png https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/14dadbfb-01b6-433b-aea0-858e4ee4aab4/Optoacoustic%2BImaging-%2B%28NBME%2BCover%2Bimage%29.png https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/795c55fd-1cbb-44c4-a5c8-1b1c465202ef/Scientific_Reports_v3.png https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/d4eff477-f0ab-4b29-8280-80bfe17b7c0d/ArthritisResearchTherapy.webp https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/c3adf263-0c06-4d38-9d64-dfa4251e838b/Surgery.gif https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/c91bd402-ffa8-470f-978d-d401e38c44fa/Optica.jpg https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/4fc1afb6-3a3c-4d79-8d53-886e645ead73/AnnalsSurgicalOncology.webp https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/795c55fd-1cbb-44c4-a5c8-1b1c465202ef/Scientific_Reports_v3.png https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/4894a7b5-a95c-4306-b931-b05af94484d4/Press+Release_v2a.png https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/f3cbec39-3c48-445f-bec6-d214f0e01dbb/Press+Release_v2b.png https://images.squarespace-cdn.com/content/v1/62059f4a5246e613b6129caf/c575f417-246a-4dd7-a74c-f5473ddd76e8/Press+Release_v2c.png